RESEARCH PROFILE
SERMORELIN
Growth Hormone Releasing Hormone Analog • GRF 1-29
Sermorelin is a synthetic 29 amino acid peptide corresponding to the biologically active portion of human growth hormone releasing hormone. It stimulates the pituitary GHRH receptor, promoting endogenous growth hormone release through the body's physiological GH axis.
PREVIOUSLY FDA APPROVED • NO CURRENT FDA APPROVED PRODUCT • HUMAN CLINICAL EVIDENCE
SERMORELIN AT A GLANCE
Category
Growth hormone releasing hormone analog
Alternate Names
Sermorelin acetate • GRF 1-29 • GHRH 1-29
Structure
29 amino acid peptide
Primary Target
GHRH receptor
Primary Research Pathway
Growth hormone • IGF-1 axis
Regulatory Status
Previously FDA approved • No currently marketed FDA approved sermorelin product
IMPORTANT DISTINCTION
Sermorelin has a different regulatory history from many research peptides.
FDA-approved sermorelin products historically existed in the United States, including Geref.
Sermorelin was used clinically as a diagnostic agent for growth hormone secretion and was later approved for treatment of certain children with growth hormone deficiency.
Those branded products were subsequently discontinued.
Therefore, it is inaccurate to describe Sermorelin as either simply “currently FDA approved” or “never FDA approved.”
The more precise description is:
Sermorelin has a history of FDA approval, but there is currently no FDA-approved sermorelin drug product marketed in the United States.
WHAT IS SERMORELIN?
Sermorelin is a synthetic analog of the naturally occurring hormone growth hormone releasing hormone, or GHRH.
Natural human GHRH contains 44 amino acids.
Research established that the first 29 amino acids contain the principal biological activity required to stimulate pituitary growth hormone release.
Sermorelin reproduces this active GHRH 1-29 sequence.
Rather than supplying growth hormone directly, Sermorelin stimulates the pituitary gland to release endogenous growth hormone.
This makes its mechanism fundamentally different from administration of recombinant human growth hormone.
Sermorelin also differs from ghrelin receptor agonists such as Ipamorelin. Sermorelin activates the GHRH receptor, while Ipamorelin primarily activates the ghrelin receptor, GHSR1a.
Its clinical and research history includes pediatric growth hormone deficiency, evaluation of pituitary GH reserve, GH-axis physiology, and research involving age-associated changes in growth hormone secretion.
MECHANISM OF ACTION
Sermorelin acts through the body's physiological hypothalamic-pituitary growth hormone pathway.
GHRH RECEPTOR
Sermorelin binds to the growth hormone releasing hormone receptor on pituitary somatotroph cells.
Activation of this receptor stimulates synthesis and release of endogenous growth hormone.
ENDOGENOUS GH RELEASE
Unlike recombinant growth hormone, Sermorelin does not directly supply GH.
Instead, it sends a GHRH-like signal to a functioning pituitary gland, encouraging release of the body's own stored growth hormone.
PHYSIOLOGICAL FEEDBACK
Growth hormone secretion remains influenced by the body's normal regulatory systems.
One important inhibitory signal is somatostatin, which suppresses GH release.
Because Sermorelin acts upstream at the pituitary rather than replacing GH directly, endogenous feedback remains relevant to the resulting response.
PULSATILE RELEASE
Normal human growth hormone secretion occurs in pulses rather than as a constant concentration.
Some of the largest physiological GH pulses occur during early sleep.
Sermorelin's relatively short duration of action has therefore made pulsatile GH-axis signaling an important part of its research and historical clinical context.
DOWNSTREAM IGF-1
Growth hormone subsequently stimulates production of insulin-like growth factor 1, or IGF-1, particularly through hepatic signaling.
IGF-1 is therefore commonly used as a downstream marker when evaluating longer-term GH-axis activity.
WHAT THE RESEARCH SHOWS
PEDIATRIC HUMAN EVIDENCE
Sermorelin has substantially more historical human clinical evidence than many contemporary research peptides.
Clinical research evaluated GHRH 1-29 and Sermorelin in children with impaired growth hormone secretion and short stature.
Studies demonstrated that Sermorelin could stimulate endogenous GH secretion in individuals with sufficient functional pituitary capacity.
This clinical evidence contributed to its historical regulatory approval.
HISTORICAL PEDIATRIC TREATMENT
Your Project profile identifies historical FDA-approved use of Sermorelin acetate for treatment of certain children with growth hormone deficiency.
Clinical research evaluated repeated Sermorelin administration and growth responses in pediatric populations.
Importantly, this evidence concerns specific pediatric populations and historical pharmaceutical products.
It should not be extrapolated automatically to anti-aging, bodybuilding, recovery, or body-composition uses in healthy adults.
DIAGNOSTIC USE
Sermorelin was also historically used as a diagnostic agent for evaluating growth hormone secretion.
Because its mechanism requires a functioning pituitary response, administration of a GHRH analog can provide information about pituitary GH reserve.
This diagnostic history further supports the biological activity of the GHRH 1-29 sequence in humans.
ADULT & AGING RESEARCH
Human research has also examined GHRH analogs in older adults and in the context of age-associated reductions in growth hormone secretion.
Some studies reported increases in GH or IGF-1 and explored changes in body composition, sleep, cognition, or other physiological measures.
However, these studies were generally small, heterogeneous, and not sufficient to establish Sermorelin as an approved anti-aging therapy.
WHAT THE EVIDENCE SUPPORTS
Human evidence supports that Sermorelin:
Activates the human GHRH receptor pathway
Stimulates endogenous pituitary growth hormone release
Can increase downstream GH-axis signaling when pituitary function is adequate
Had historical clinical utility in specific pediatric and diagnostic settings
WHAT HAS NOT BEEN ESTABLISHED
Current evidence does not establish Sermorelin as an FDA-approved treatment for:
Anti-aging
Longevity
Body recomposition
Fat loss
Muscle growth in healthy adults
Athletic performance
Exercise recovery
Sleep enhancement
IMPORTANT EVIDENCE LIMITATION
The existence of historical FDA approval is important evidence of pharmacological activity and prior clinical use.
It does not mean that every modern use of Sermorelin is FDA approved or supported by the same evidence.
Historical pediatric and diagnostic evidence should not be repurposed as proof of effectiveness for unrelated adult wellness or performance claims.
SAFETY & RESEARCH CONSIDERATIONS
Sermorelin has a historical clinical safety record, but risks still depend on the population, product, indication, exposure, and individual health status.
COMMONLY REPORTED EFFECTS
Your Project profile identifies injection-site reactions as among the most frequently reported effects.
These can include:
Pain
Redness
Swelling
Irritation
Other reported effects include:
Headache
Flushing
Dizziness
Nausea
Sleepiness or hyperactivity
Hives or urticaria
ALLERGIC REACTIONS
Hypersensitivity reactions are possible.
Persistent hives, facial swelling, difficulty breathing, or other signs of a serious allergic reaction require prompt medical evaluation.
ANTIBODY DEVELOPMENT
Historical pediatric research reported development of anti-GRF antibodies in some participants.
Your Project profile notes that approximately 20% of FDA-era trial participants developed antibodies during treatment, while available evidence did not clearly demonstrate that these antibodies eliminated growth response.
This remains relevant when discussing the immunogenic potential of peptide therapies.
GLUCOSE & INSULIN SENSITIVITY
Growth hormone can influence glucose metabolism and insulin sensitivity.
Monitoring glucose regulation can therefore be relevant when GH-axis stimulation is prolonged, particularly in people with diabetes, prediabetes, or other metabolic risk factors.
FLUID RETENTION
GH-axis stimulation can contribute to fluid retention.
Persistent edema, neurological symptoms, shortness of breath, or significant swelling warrant medical assessment rather than being assumed to be routine effects.
GH, IGF-1 & CELL GROWTH
Growth hormone and IGF-1 participate in normal cellular growth and proliferation.
Your Project source therefore identifies active malignancy or significant cancer history as an important area requiring clinician review before GH-axis stimulation is considered.
This is a pathway-based precaution and does not establish that Sermorelin causes cancer.
PITUITARY FUNCTION MATTERS
Because Sermorelin depends on the pituitary gland to produce and release GH, its biological response depends partly on pituitary function.
Individuals with significant pituitary dysfunction may therefore respond differently from individuals with intact pituitary reserve.
REGULATORY CONTEXT
SERMORELIN HAS A HISTORY OF FDA APPROVAL
Sermorelin's regulatory history is unusual among compounds in the Croix research library.
Your Project profile documents the following historical sequence:
1982
The active GHRH 1-29 sequence was identified.
1990
Sermorelin received FDA approval as a diagnostic agent for evaluating growth hormone secretion.
1997
FDA approval expanded to treatment of certain children with growth hormone deficiency, including branded Geref products.
2008
Commercial Sermorelin products were discontinued.
DISCONTINUATION WAS NOT ATTRIBUTED TO SAFETY OR EFFECTIVENESS
Your Project profile states that FDA subsequently determined that the discontinued Sermorelin products were not withdrawn from sale for reasons of safety or effectiveness.
That distinction matters.
Product discontinuation does not erase Sermorelin's historical approval, but it also does not create a currently marketed FDA-approved Sermorelin product.
CURRENT STATUS
As reflected in your Project source:
There is currently no FDA-approved branded Sermorelin product marketed in the United States.
Modern compounded Sermorelin preparations should therefore not be represented as though they are the historically FDA-approved Geref product.
COMPOUNDING CONTEXT
Your Project profile states that, as of its June 2026 regulatory review, Sermorelin remained in 503A Category 1, meaning it could remain eligible for compounding by appropriately licensed 503A pharmacies while FDA's evaluation of nominated bulk substances continued.
Category 1 status is not FDA approval.
It does not mean a compounded Sermorelin preparation has undergone FDA premarket review for safety, effectiveness, quality, or manufacturing consistency.
Because this regulatory framework can change, current FDA status should be rechecked whenever the website undergoes a substantive regulatory update.
IMPORTANT REGULATORY DISTINCTION
Historical FDA approval ≠ current FDA-approved product
and
503A compounding eligibility ≠ FDA approval
Those distinctions should remain explicit anywhere Sermorelin's regulatory history is discussed.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
LOT SPECIFIC ANALYTICAL DOCUMENTATION
Analytical documentation is displayed only when Croix has a corresponding laboratory report that can be matched to the specific product and lot.
No matching Sermorelin COA is currently displayed.
IMPORTANT COA LIMITATION
When analytical documentation becomes available, results should apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix requires the product, strength, lot or batch, sample ID, laboratory, and report date to be matched before analytical documentation is represented as supporting a product.
A passing COA does not establish FDA approval, clinical efficacy, medical suitability, or the characteristics of unrelated lots.
SELECTED RESEARCH & REFERENCES
Müller EE, Locatelli V, Cocchi D.
Neuroendocrine control of growth hormone secretion.
Research and review literature describing physiological control of the growth hormone axis and GHRH signaling.
Walker RF.
Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?
Clinical Interventions in Aging. 2006.
Review discussing Sermorelin and GHRH-based stimulation of endogenous GH secretion.
Corpas E, Harman SM, Blackman MR.
Human research examining growth hormone releasing hormone administration in older adults.
Relevant to investigation of age-associated changes in the GH/IGF-1 axis.
Mayo Clinic
Sermorelin — route, side effects, and clinical information.
Historical clinical reference information concerning Sermorelin.
U.S. Food & Drug Administration
Materials concerning discontinued Sermorelin drug products and FDA's determination regarding withdrawal for reasons of safety or effectiveness.
U.S. Food & Drug Administration
503A bulk drug substance and Pharmacy Compounding Advisory Committee materials concerning Sermorelin.
EVIDENCE NOTE
Sermorelin has genuine historical human clinical evidence and a history of FDA-approved medical use.
That evidence should be distinguished from contemporary claims involving anti-aging, bodybuilding, fat loss, recovery, longevity, or general wellness, which were not the basis of its historical approvals and are not established FDA-approved indications.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish a modern Sermorelin product as FDA approved, safe, or effective for personal use.
Sermorelin has a history of FDA-approved diagnostic and pediatric therapeutic use, but those branded products were discontinued and there is currently no FDA-approved Sermorelin product marketed in the United States.
Historical FDA approval should not be interpreted as establishing contemporary compounded Sermorelin products as FDA approved or as validating unrelated uses involving anti-aging, body composition, recovery, sleep, athletic performance, or longevity.
Compounding eligibility and FDA approval are separate regulatory concepts.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.